New Monoclonal Antibodies to Clostridia GDH
Complete the form below to unlock access to ALL audio articles.
Clostridium difficile associated diarrhea (CDAD) is the leading cause of nosocomial diarrhea. The spread of this bacterium is difficult to control due to its resistant spores that survive on many surfaces.
Thus rapid detection is crucial to its control.
Most rapid tests target the toxins (A & B) produced during the infection. Another diagnostic target is glutamate dehydrogenase (GDH), an enzyme produced and released during bacterial growth.
Studies have shown that adding GDH detection together with toxin detection by EIA or PCR significantly improves assay specificity.
ViroStat has announced the release of three new monoclonal antibodies to Clostridia GDH validated by ELISA. These antibodies represent a new set of tools for rapid detection development.
